MagnetOs Clinical Evidence

Early radiographic and clinical outcomes of three patients undergoing open instrumented posterolateral fusion surgery with MagnetOs Easypack Putty

Abstract
An important factor influencing spinal fusion outcomes is the choice of bone graft. Autograft is considered the gold standard bone grafting material. However, harvesting quality autologous bone from the iliac crest may require an additional procedure and can lead to complications such as extraction site pain.

Next-generation calcium phosphate bone grafts provide surgeons an option without added cells, growth factors, or the need for autologous bone. MagnetOs is a biphasic calcium phosphate bone graft with a unique needle-shaped submicron surface topography. The surface of MagnetOs predictably polarizes M2 macrophages, which in turn secrete chemokines that stimulate mesenchymal stem cell (MSC) recruitment. Signaling from M2 macrophage cytokines stimulate MSCs to differentiate into osteoblasts, which lay down osteoid for healthy bone formation. To optimize the handling characteristics of MagnetOs biphasic calcium phosphate granules, MagnetOs Easypack Putty was developed containing a polyethylene glycol-polylactic acid (PEG-PLA) polymer.

This study includes three clinical cases where MagnetOs Easypack Putty was used on-label in the posterolateral spine. Patient reported outcomes demonstrate favorable outcomes using MagnetOs Easypack Putty.

MagnetOs is not cleared by the FDA as an osteoinductive bone graft.
Results from in vivo and in vitro laboratory testing may not be predictive of clinical experience in humans.
Please refer to the Instructions for Use for a full list of indications, contradindications, precautions, and warnings.

PROMO/MAG/GL/081-24/R00